About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

Latest Press Releases

Date Title and Summary
Toggle Summary Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  Genomic Health , Inc.  (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients
Toggle Summary NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
- Only test recommended based on its ability to predict chemotherapy benefit - Recommendation expanded to include patients with micrometastatic disease REDWOOD CITY, Calif. , Dec. 19, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health
Toggle Summary Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Toggle Summary Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), reinforcing the value of the Oncotype DX ® test in


The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.